PT - JOURNAL ARTICLE AU - Kim, Jinyong AU - Chang, Euijin AU - Park, Song Yi AU - Lee, Dae-Won AU - Kang, Chang Kyung AU - Choe, Pyoeng Gyun AU - Kim, Nam Joong AU - Oh, Myoung-don AU - Park, Wan Beom AU - Lee, Kyung-Hun AU - Im, Seock-Ah TI - Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment AID - 10.1101/2022.07.23.22277888 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.23.22277888 4099 - http://medrxiv.org/content/early/2022/07/24/2022.07.23.22277888.short 4100 - http://medrxiv.org/content/early/2022/07/24/2022.07.23.22277888.full AB - Background Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data is available on their efficacy in patients under active anti-cancer therapies.Materials and Methods In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the anti-spike protein subunit 1 of SARS-CoV-2 after vaccination in early breast cancer patients with concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no treatments.Results Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the post-vaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy.Conclusion Our study emphasizes the importance of the personalized risk stratification and consideration for booster doses in more vulnerable populations.Implications for Practice In this article, we present rare data on the homogeneous population of patients with early breast cancer under active anti-cancer treatments. The patients showed adequate serologic responses against SARS-CoV-2 virus after standard doses of vaccination without serious adverse events in concurrence with active adjuvant anti-cancer therapy. The patients receiving concurrent cytotoxic chemotherapy, however, have significantly lower serum anti-spike antibody titers than those under non-cytotoxic anti-cancer treatments or without treatments. Selection of the COVID-19 vaccines should be based on personalized risk stratification considering the use of concurrent cytotoxic chemotherapy and the patient’s medical circumstances. Booster doses of vaccination could be considered for the vulnerable population, such as elderly with comorbidities and the single standard dose of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grant no 04-2021-0250 from the SNUH Research Fund and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIT)(2021M3A9I2080498)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2103-121-1206).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.